OIS@AAO

The IPO market in ophthalmology may have cooled off last year, but that only mirrored what’s happened in healthcare overall. In this video from OIS@AAO…

Jonathan Norris, managing director at Silicon Valley Bank, delivered his overview of private investing in health care in 2016. Among the high points: Investments in…

Dosing of the suprachoroidal space with Zuprata, Clearside Biomedical’s proprietary triamcinolone formulation, can provide high bioavailability of drug to the retina and choroid while avoiding…

The OIS Index, a composite of ophthalmic growth stocks, was introduced at OIS@AAO. The purpose of the OIS Index is to provide a tool for…

Since a congressional mandate required the National Institutes of Health to set aside 3% of its total funding for small business grants, the National Eye…

CHICAGO—Some of the world’s largest ophthalmic companies were represented here during OIS@AAO to discuss what it takes to build a successful ophthalmic franchise. Panel moderator…

CHICAGO—This year’s OIS Industry Tribute celebrated one of the best-known names in ophthalmology: Allergan. The Dublin-based company is one that “we rely on for innovation…

The methodology private and government payers use to measure quality outcomes in health care is changing, David W. Parke II, MD, CEO of the American…

Ophthalmology remains one of the likeliest targets for technology companies looking to make an impact – and to build a business – within health care.…

Ashley McEvoy, company group chairman, Johnson & Johnson Vision, shares why ophthalmology is attractive to J&J and other players. In discussing Abbott Medical Optics, McEvoy…

CHICAGO—A combination of phenylephrine 1% and ketorolac 0.3% injection is “the first and only FDA-approved intraocular product to prevent miosis and to reduce postop ocular…